Gan & Lee Pharmaceuticals (603087.SS) on Tuesday said its investigational once-weekly insulin GZR4 Injection met primary endpoints in two Phase 3 trials, demonstrating superior blood sugar control versus daily insulin treatments.
The SUPER-1 trial, conducted in insulin-naïve patients with type 2 diabetes, showed GZR4 achieved a greater reduction in HbA1c compared to insulin glargine (Lantus), with a mean decrease of 1.45% versus 1.22% after 26 weeks.
In the SUPER-2 trial, involving patients previously treated with basal insulin, GZR4 also outperformed insulin degludec (Tresiba), delivering a 1.00% reduction versus 0.58% in HbA1c.
Across both studies, GZR4 achieved higher rates of target blood sugar control without significant hypoglycemia, while showing a favorable safety and tolerability profile. No severe hypoglycemic events were reported.
The company said the once-weekly regimen could reduce injection frequency by more than 85% compared to daily insulin, potentially improving treatment adherence and long-term outcomes for patients with type 2 diabetes.
Gan & Lee plan to present detailed results at upcoming scientific meetings and submit findings for publication, as they continue late-stage development of GZR4 as a potential next-generation basal insulin therapy.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.